312 related articles for article (PubMed ID: 17236209)
41. HIV-1 viral RNA is selected in the form of monomers that dimerize in a three-step protease-dependent process; the DIS of stem-loop 1 initiates viral RNA dimerization.
Song R; Kafaie J; Yang L; Laughrea M
J Mol Biol; 2007 Aug; 371(4):1084-98. PubMed ID: 17599354
[TBL] [Abstract][Full Text] [Related]
42. X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor SDZ283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations.
Ringhofer S; Kallen J; Dutzler R; Billich A; Visser AJ; Scholz D; Steinhauser O; Schreiber H; Auer M; Kungl AJ
J Mol Biol; 1999 Mar; 286(4):1147-59. PubMed ID: 10047488
[TBL] [Abstract][Full Text] [Related]
43. [Mechanism of action of aspartic proteases. III. Conformational characteristics of HIV-1 protease inhibitor JG-365].
Popov ME; Kashparov IV; Rumsh LD; Popov EM
Bioorg Khim; 1999 Jun; 25(6):418-22. PubMed ID: 10505229
[TBL] [Abstract][Full Text] [Related]
44. Solution structure of a double mutant of the carboxy-terminal dimerization domain of the HIV-1 capsid protein.
Wong HC; Shin R; Krishna NR
Biochemistry; 2008 Feb; 47(8):2289-97. PubMed ID: 18220423
[TBL] [Abstract][Full Text] [Related]
45. Drug resistance of HIV-1 protease against JE-2147: I47V mutation investigated by molecular dynamics simulation.
Bandyopadhyay P; Meher BR
Chem Biol Drug Des; 2006 Feb; 67(2):155-61. PubMed ID: 16492163
[TBL] [Abstract][Full Text] [Related]
46. HIV-1 protease folding and the design of drugs which do not create resistance.
Broglia R; Levy Y; Tiana G
Curr Opin Struct Biol; 2008 Feb; 18(1):60-6. PubMed ID: 18160276
[TBL] [Abstract][Full Text] [Related]
47. A unidirectional crosslinking strategy for HIV-1 protease dimerization inhibitors.
Hwang YS; Chmielewski J
Bioorg Med Chem Lett; 2004 Aug; 14(16):4297-300. PubMed ID: 15261290
[TBL] [Abstract][Full Text] [Related]
48. Structural and kinetic analysis of pyrrolidine-based inhibitors of the drug-resistant Ile84Val mutant of HIV-1 protease.
Böttcher J; Blum A; Heine A; Diederich WE; Klebe G
J Mol Biol; 2008 Nov; 383(2):347-57. PubMed ID: 18692068
[TBL] [Abstract][Full Text] [Related]
49. A phenylnorstatine inhibitor binding to HIV-1 protease: geometry, protonation, and subsite-pocket interactions analyzed at atomic resolution.
Brynda J; Rezacova P; Fabry M; Horejsi M; Stouracova R; Sedlacek J; Soucek M; Hradilek M; Lepsik M; Konvalinka J
J Med Chem; 2004 Apr; 47(8):2030-6. PubMed ID: 15056001
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.
Narendra Babu SN; Rangappa KS
Bioorg Med Chem; 2008 Jan; 16(2):874-80. PubMed ID: 17981043
[TBL] [Abstract][Full Text] [Related]
51. A peptide inhibitor of HIV-1 protease using alpha, beta- dehydro residues: a structure based computer model.
Siddiqui MI; Kataria S; Ahuja V; Rao GS
Indian J Biochem Biophys; 2001; 38(1-2):90-5. PubMed ID: 11563339
[TBL] [Abstract][Full Text] [Related]
52. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
[TBL] [Abstract][Full Text] [Related]
53. Molecular tongs containing amino acid mimetic fragments: new inhibitors of wild-type and mutated HIV-1 protease dimerization.
Bannwarth L; Kessler A; Pèthe S; Collinet B; Merabet N; Boggetto N; Sicsic S; Reboud-Ravaux M; Ongeri S
J Med Chem; 2006 Jul; 49(15):4657-64. PubMed ID: 16854071
[TBL] [Abstract][Full Text] [Related]
54. Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation.
Sluis-Cremer N; Arion D; Abram ME; Parniak MA
Int J Biochem Cell Biol; 2004 Sep; 36(9):1836-47. PubMed ID: 15183348
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of HIV protease by monoclonal antibodies.
Rezacova P; Brynda J; Fabry M; Horejsi M; Stouracova R; Lescar J; Chitarra V; Riottot MM; Sedlacek J; Bentley GA
J Mol Recognit; 2002; 15(5):272-6. PubMed ID: 12447903
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F
J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016
[TBL] [Abstract][Full Text] [Related]
57. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
58. The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease.
Misumi S; Kudo A; Azuma R; Tomonaga M; Furuishi K; Shoji S
Biochem Biophys Res Commun; 1997 Dec; 241(2):275-80. PubMed ID: 9425262
[TBL] [Abstract][Full Text] [Related]
59. Convergent chemical synthesis and crystal structure of a 203 amino acid "covalent dimer" HIV-1 protease enzyme molecule.
Torbeev VY; Kent SB
Angew Chem Int Ed Engl; 2007; 46(10):1667-70. PubMed ID: 17397076
[No Abstract] [Full Text] [Related]
60. Toward the first nonpeptidic molecular tong inhibitor of wild-type and mutated HIV-1 protease dimerization.
Vidu A; Dufau L; Bannwarth L; Soulier JL; Sicsic S; Piarulli U; Reboud-Ravaux M; Ongeri S
ChemMedChem; 2010 Nov; 5(11):1899-906. PubMed ID: 20936621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
